Apalutimide Plus ADT Improves Survival in Nonmetastatic Castration-Resistant Prostate Cancer
Final data analysis of SPARTAN trial demonstrates large benefit in overall survival when compared with ADT plus placebo.
CONCLUSIONS The current study presented a landscape view of possible underlying mechanism of insulin resistance by bioinformatics analysis based on validated IRRGs. PMID: 32651353 [PubMed - as supplied by publisher]
Given the increasing role of genetic testing in the treatment of prostate cancer, physicians and patients must understand limits of federal privacy law, an expert said at a recent AUA session.Medscape Medical News
Publication date: Available online 11 July 2020Source: Journal of Functional FoodsAuthor(s): Khalid Z. Masoodi, Wasia Wani, Zahoor A. Dar, Sheikh Mansoor, Syed Anam-ul-Haq, Iqra Farooq, Khursheed Hussain, Shafiq A. Wani, Firdos A. Nehvi, Nazeer Ahmed
The objective of this study was to validate the discriminatory power of these subregions with respect to the whole organs, in a large independent population.
This study investigates the role of prostate surface antigen (PSA) kinetics as a predictor of progression in mHSPC patients treated with AA/P.Patients and MethodsAll patients with mHSPC who initiated androgen deprivation therapy (ADT) and AA/P from June 2017 to February 2019 at the Cleveland Clinic were eligible. PSA-mCRPC was defined as a PSA rise at two consecutive time points. Patients were followed until first mCRPC or last contact after AA/P. Patterns of PSA change were evaluated using a longitudinal mixed model at time 0, 3, 6, 9, and 12 months from AA/P initiation. The association between PSA profile at 3 ...
Conclusions99mTc might not be the ideal radionuclide for Auger therapy but can be useful to validate the design of new classes of Auger-electron emitting radioconjugates. In this context, our results highlight the crucial importance of the distance of Auger electron emitters to the target DNA and encourage the development of strategies for the fine tuning of the distance to DNA for other medical radionuclides (e.g.,111In or161Tb) in order to enhance their radiotherapeutic effects within the Auger therapy of cancer.
Publication date: Available online 12 July 2020Source: Seminars in Cancer BiologyAuthor(s): Bo Ma, Alan Wells, Liang Wei, Junnian Zheng
Publication date: Available online 12 July 2020Source: Acta Pharmaceutica Sinica BAuthor(s): Jianwei Zheng, Junfeng Wang, Qian Wang, Hongye Zou, Hong Wang, Zhenhua Zhang, Jianghe Chen, Qianqian Wang, Panxia Wang, Yueshan Zhao, Jing Lu, Xiaolei Zhang, Songtao Xiang, Haibin Wang, Jinping Lei, Hong-Wu Chen, Peiqing Liu, Yonghong Liu, Fanghai Han, Junjian Wang